Novartis Aims To Fly High In Kidney Disease With Chinook Buy

Paying $3.2bn Upfront For Two Phase III IgAN Drugs

 
• By Kevin Grogan

Buying Chinook will add a pair of late-stage programs to Novartis's IgAN portfolio which is currently headed by iptacopan but the proposed deal could attract the attention of the FTC.

Chinook
Chinook Lifted By Novartis Interest • Source: Shutterstock

Novartis AG has jumped onto the M&A merry-go-round to pick up Chinook Therapeutics Inc., paying $3.2bn upfront to get hold of two late-stage drugs for the rare kidney disease IgA nephropathy (IgAN).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business